BIOPATCH® highlighted as one of the UK’s top potential health innovations


Intravenous products: Ethicon, Inc report “The unique action of BIOPATCH® was identified among an exclusive 108 products as having the potential to make a real difference to patients¹. The catalogue clarifies that BIOPATCH®, a globally used product, supports the fundamental domains of the committee by preventing people from dying prematurely, helping patients to recover from episodes of ill-health, ensuring a positive experience of care and treating and caring for people in a safe environment and protecting them from avoidable harm¹.

In a press release from Ethicon, Inc describe how BIOPATCH® was highlighted as one of the UK’s top potential health innovations.

“Ethicon, Inc.’s BIOPATCH® has been recognised as a pioneering product with its recent inclusion in the NHS Catalogue of Potential Innovations.¹ This acknowledgment is not only a testament to the product’s extensive evidence base but also encourages service improvement leaders to consider BIOPATCH® as an innovation that can support good patient care.

BIOPATCH®, an antimicrobial dressing with Chlorhexidine Gluconate (CHG), helps to reduce local infections, catheter-related blood stream infections (CRBSI), and skin colonisation of microorganisms commonly related to CRBSI, in patients with central venous or arterial catheters.² The catalogue notes that BIOPATCH® reduces CRBSIs by up to 69 percent³ and is proven to kill the most common pathogens such as MRSA & MSSA.4

“We have always believed that BIOPATCH® is an innovative product. We are pleased that the Department of Health’s, Innovation, Health and Wealth organisaton shares this view and recognises the benefits of BIOPATCH®. Some hospitals are saving hundreds of thousands of pounds, simply by reducing their CRBSI rates with the implementation of BIOPATCH® as part of their bundle of care. Our aim is always to ensure that hospital CRBSI rates are further reduced and that we contribute to improving patient outcomes.” Andrew Cleworth, Business Manager BIOPATCH UK, Ireland, Nordics.

Without the use of BIOPATCH®, resident bacteria quickly re-colonise on the skin’s surface following antiseptic application.5 BIOPATCH®’s unique mode of action works by gradually releasing the antimicrobial and antifungal CHG from the hydrophilic foam matrix.¹ This unique action contributes to the reduction of CRBSIs by up to 69 percent.³

Recent statistics from NICE have shown that 300,000 patients per year suffer from healthcare acquired infections (HAI) of which 18 percent (or 54,000) are attributed to CRBSIs.¹ As the majority of these infections come from the patient’s own skin,6 it can be very challenging to predict which patients may be susceptible to infection. For this reason and as evidence shows³ BIOPATCH® has been a proven CRBSI preventative and is increasingly considered as the standard of care.

The issues of infection and antimicrobial infections were recently highlighted in a report7 by England’s Chief Medical Officer, Professor Dame Sally Davies. Professor Davies stated that: ‘It is essential that we continue to develop our defences against infectious disease and to do this we must align policy, science, innovation and clinical excellence.” The report provides further support of the importance of prevention of infections in hospitals that can potentially lead to threats to life.”


1. NHS: Innovation Health and Wealth. Catalogue of Potential Innovations. 2013; 1-65
2. BIOPATCH® Antimicrobial Dressing with Chlorhexidine Gluconate. Instructions for use. Johnson and Johnson Wound Management.
3. Timsit JF, et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomised controlled trial. JAMA 2009; 301 (12):1231-1241.
4. Bhende S, Spangler D. In vitro assessment of chlorhexidine gluconate-impregnated polyurethane foam antimicrobial dressing using zone of inhibition assays Infection Control and Hospital Epidemiology 2004;25(8):664-667.
5. Hendley JO, et al. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin. Antimicrobial Agents and Chemotherapy. April 1991;35(4):627-631
6. Safdar N, et al. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intensive Care Med. 2004;30:62-67
7. Davies, S. Annual Report of the Chief Medical Officer, Volume Two, Infections & The Rise of Antimicrobial Resistance, 2011.12-13

Main page


Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.